Endometrial Cancer Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Patient Pool, Prevalence and Companies DelveInsight

(Albany, USA) DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Endometrial Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
The Endometrial Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometrial Cancer pipeline products will significantly revolutionize the Endometrial Cancer market dynamics.

To Know in detail about the Endometrial Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometrial Cancer Market Forecast - https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Endometrial Cancer Market Report:
• The Endometrial Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This approval broadens the previous indication for Jemperli plus chemotherapy in the European Union (EU) to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represent approximately 75% of patients diagnosed with endometrial cancer and who have limited treatment options.
• In August 2024, GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This approval broadens the previous indication for Jemperli plus chemotherapy to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors who represent 70-75% of patients diagnosed with endometrial cancer and who have limited treatment options. The supplemental Biologics License Application (sBLA) supporting this expanded indication received Priority Review and was approved ahead of the Prescription Drug User Fee Act action date.
• In May 2024, Eli Lilly shared findings from the EMBER phase 1a/1b study at the ASCO annual meeting 2024, presenting results of imlunestrant both as monotherapy and in combination with abemaciclib in endometrioid endometrial cancer.
• The results from the Phase III RUBY trial, which focused on patients with primary advanced endometrial cancer (EC) showing mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H), were presented at the 2024 ASCO annual meeting.
• According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives
• 80 percent of people with uterine cancer survive for five years or longer after receiving the diagnosis. Endometrial cancer comprises about 4% of all cancers in women globally
• According to the American cancer society, in the United States, the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs
• As per Cancer Research UK, there are around 9,700new uterine cancer cases in the UK every year, that is 27 every day (2016-2018). Among females in the UK, uterine cancer is the 4th most common cancer,with around 9,700 new cases in 2017
• According to the study by Aoki et al. ) 2020), about 380 000 new cases of endometrial cancer occur every year in the world, and about 89,000 deaths are confirmed annually. Endometrial cancer is the 10th most common cause of cancer in women in Japan, with more than 14,900 new patients diagnosed per year in recent years
• Key Endometrial Cancer Companies: Eli Lilly, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others
• Key Endometrial Cancer Therapies: Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others

Endometrial Cancer Overview
Endometrial cancer is one of the most common gynecological malignancies, primarily affecting postmenopausal women. It begins in the lining of the uterus, known as the endometrium, and is often detected early due to symptoms like abnormal vaginal bleeding. Endometrial cancer diagnosis typically involves transvaginal ultrasound, endometrial biopsy, or hysteroscopy. Endometrial cancer types are broadly classified into Type I (estrogen-dependent) and Type II (non-estrogen dependent), with Type I being more common and having a better prognosis. Endometrial cancer risk factors include obesity, diabetes, hormone replacement therapy, late menopause, and a history of PCOS or Lynch syndrome.
Endometrial cancer treatment varies based on the stage and type, commonly involving surgery (hysterectomy), radiation therapy, chemotherapy, and increasingly, endometrial cancer immunotherapy or hormone therapy for advanced or recurrent cases. The market for endometrial cancer therapeutics is expanding due to ongoing research, improved endometrial cancer diagnostics, and the emergence of targeted treatments. However, endometrial cancer challenges such as late-stage detection in certain populations and limited therapeutic options for aggressive subtypes remain. Rising awareness, improved screening techniques, and personalized medicine are expected to play crucial roles in improving endometrial cancer survival rates and patient outcomes globally.

Get a Free sample for the Endometrial Cancer Market Report: https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Market
The dynamics of the Endometrial Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Endometrial Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometrial Cancer Epidemiology Segmentation:
The Endometrial Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of Endometrial Cancer in the 7MM
• Stage-specific Cases of Endometrial Cancer in the 7MM
• Age-specific Cases of Endometrial Cases in the 7MM
• Drug Treatment Population by Line in the 7MM

Download the report to understand which factors are driving Endometrial Cancer epidemiology trends @ Endometrial Cancer Epidemiological Insights - https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometrial Cancer market or expected to get launched during the study period. The analysis covers Endometrial Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endometrial Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endometrial Cancer Therapies and Key Companies
• Imlunestrant: Eli Lilly
• Lynparza (Olaparib) + Imfinzi DuO-E: AstraZeneca
• Selinexor: Karyopharm Therapeutics
• EG-007: Evergreen Therapeutics

Endometrial Cancer Market Strengths
Significant developments during the last decade have altered the clinical management of patients with endometrial cancer and emphasized the need for standardized grossing and reporting of surgical resection specimens as well as morphologic assessment and ancillary testing for accurate classification of endometrial carcinomas.

Request for sample report @ https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Market Opportunities
Emerging areas of therapeutic interest in the treatment of endometrial cancer lie in immunotherapy combinations, in DNA repair, and in incorporating molecular subgroups into clinical practice.
The treatment for endometrial cancer is rapidly evolving with the development of molecular analysis and novel strategies.

Scope of the Endometrial Cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Endometrial Cancer Companies: AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others
Key Endometrial Cancer Therapies: Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others
Endometrial Cancer Therapeutic Assessment: Endometrial Cancer current marketed and Endometrial Cancer emerging therapies
Endometrial Cancer Market Dynamics: Endometrial Cancer market drivers and Endometrial Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Endometrial Cancer Unmet Needs, KOL's views, Analyst's views, Endometrial Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Endometrial Cancer market share @ Endometrial Cancer Treatment Landscape - https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Endometrial Cancer Market Report Introduction
2. Executive Summary for Endometrial Cancer
3. SWOT analysis of Endometrial Cancer
4. Endometrial Cancer Patient Share (%) Overview at a Glance
5. Endometrial Cancer Market Overview at a Glance
6. Endometrial Cancer Disease Background and Overview
7. Endometrial Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Endometrial Cancer
9. Endometrial Cancer Current Treatment and Medical Practices
10. Endometrial Cancer Unmet Needs
11. Endometrial Cancer Emerging Therapies
12. Endometrial Cancer Market Outlook
13. Country-Wise Endometrial Cancer Market Analysis (2020-2034)
14. Endometrial Cancer Market Access and Reimbursement of Therapies
15. Endometrial Cancer Market Drivers
16. Endometrial Cancer Market Barriers
17. Endometrial Cancer Appendix
18. Endometrial Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.